As a result, various FASN inhibitors were developed as anticancer drugs, but most of them failed in clinical trials with the exception of TVB-2640, which is currently undergoing phase 2 clinical trials in combination with other drugs for HER2+ breast cancer [12,13]. The gene discussed is FASN; the disease is breast cancer.